Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Aug 25:14:1541-1551.
doi: 10.2147/PPA.S235104. eCollection 2020.

Transdermal Asenapine in Schizophrenia: A Systematic Review

Affiliations
Review

Transdermal Asenapine in Schizophrenia: A Systematic Review

Brennan Carrithers et al. Patient Prefer Adherence. .

Abstract

Background: Asenapine is a novel antipsychotic that has demonstrated efficacy in controlling psychosis in schizophrenia and mania in bipolar illness. It must be administered as a sublingual formulation because it is nearly completely metabolized in the first pass through the liver. Recently, a transdermal formulation of asenapine has been approved for schizophrenia by the Food and Drug Administration.

Methods: A systematic review of transdermal asenapine was done utilizing the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) model.

Discussion: There are several formulations of transdermal asenapine but only Secuado® has been approved for clinical use. Total bioavailability is 35%. Peak plasma concentration (Cmax) is 4 ng/mL and occurs within 1 hr (Tmax); elimination half-life (t1/2) is 24 hrs (range 13.4 to 39.2 h). Asenapine is highly bound (95%) to albumin and α1-acid glycoprotein. It has a unique receptor profile in which it functions as an antagonist at multiple receptors with affinity that is higher than D2 (Ki = 1.3) including D3, D4, 5HT2A, 5HT2C, 5HT2B, 5HT7, 5HT6, H1, and α2. This profile suggests that asenapine may be of particular value off label for bipolar depression, anxiety, and aggression. Transdermal asenapine was only tested in one randomized, placebo-controlled study of acute psychosis in schizophrenia. It was superior to placebo at week 6 with nearly one-third of patients experiencing >30% improvement in total PANSS score which translates in a number needed to treat (NNT) of 9.

Keywords: antipsychotic; asenapine; schizophrenia; topical; transdermal.

PubMed Disclaimer

Conflict of interest statement

Dr Rif S El-Mallakh reports personal fees from Alkermes, Indivior, Intra-Cellular Therapeutics, Janssen, Lundbeck, Otsuka, Sunovion, and Teva, outside the submitted work. The authors report no other conflicts of interest in this work.

Figures

Figure 1
Figure 1
The chemical structure of asenapine. (image courtesy PubChem).
Figure 2
Figure 2
Change in PANSS score in subjects with acute schizophrenia and baseline score of 97.4 (placebo), 97.0 (low dose), and 95.6 (high dose). Data From Citrome et al’s study.
Figure 3
Figure 3
Response rates over time in in subjects with acute schizophrenia treated with low-dose transdermal asenapine (3.8 mg/24 hours), high-dose transdermal asenapine (7.6 mg/24 hours), and placebo. Only week 6 is significantly higher than placebo for both doses (P < 0.05). Data from Citrome et al’s study.

References

    1. United Ststes Food and Drug Administration (USFDA). Press Announcements: FDA Approves Saphris to Treat Schizophrenia and Bipolar Disorder; 2009. Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm177401.html. Accessed June29 2020.
    1. Citrome L, Zeni CM, Correll CU. Patches: established and emerging transdermal treatments in psychiatry. J Clin Psychiatry. 2019;80(4):18nr12554. doi: 10.4088/JCP.18nr12554. - DOI - PubMed
    1. Citrome L, Walling D, Zeni C, Komaroff M, Park A Efficacy and safety of an asenapine transdermal system (HP-3070) for treatment of adults with schizophrenia: a Phase 3 randomized, placebo-controlled, inpatient study. Presented at: Psych Congress 2019; October 3-6, 2019; San Diego, CA: Poster 122.
    1. Mohr P, Rietscher R, Eifler R, Bourquain O, inventors. LTS Lohmann Therapie-Systeme AG, Andernach, Germany, applicant. Transdermal therapeutic system containing asenapine and polysiloxane or polyisobutylene. WO2018115010A1; 2018.
    1. Mohr P, Rietscher R, Eifler R, Bourquain O, inventors. LTS Lohmann Therapie-Systeme AG, Andernach, Germany, applicant. Transdermal therapeutic system containing asenapine and silicone acrylic hybrid polymer. WO2019002204A1; 2019.

LinkOut - more resources